^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    golcadomide (CC-99282)

    i
    Other names: CC-99282, BMS-986369, BMS986369, CC99282, BMS 986369, CC 99282
    Associations

    News

    Trials
    Company:
    BMS
    Drug class:
    Cereblon modulator, CRL4-CRBN E3 ubiquitin ligase modulator
    Related drugs:
    Associations

    News

    Trials
    1d
    A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) (clinicaltrials.gov)
    P1/2, N=85, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK negative
    |
    golcadomide (CC-99282)
    1m
    CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Nathan Denlinger | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    clonoSEQ
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar) • golcadomide (CC-99282)
    2ms
    GOLSEEK-1: Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (clinicaltrials.gov)
    P3, N=850, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • golcadomide (CC-99282)
    2ms
    A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas (clinicaltrials.gov)
    P1/2, N=49, Recruiting, The Lymphoma Academic Research Organisation | Not yet recruiting --> Recruiting
    Enrollment open
    |
    azacitidine • golcadomide (CC-99282) • roginolisib (IOA-244)
    2ms
    Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment (clinicaltrials.gov)
    P1, N=29, Completed, Celgene | Recruiting --> Completed
    Trial completion
    |
    golcadomide (CC-99282)
    3ms
    GOLSEEK-2: A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Rituxan (rituximab) • cyclophosphamide • pegylated liposomal doxorubicin • vincristine • prednisone • bendamustine • golcadomide (CC-99282)
    4ms
    Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma (clinicaltrials.gov)
    P2, N=36, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial primary completion date
    |
    Gazyva (obinutuzumab) • golcadomide (CC-99282)
    4ms
    Go-Pro-DLBCL: Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=20, Not yet recruiting, Seoul National University Hospital
    New P1/2 trial
    |
    Rituxan (rituximab) • golcadomide (CC-99282) • poseltinib (HM71224)
    5ms
    CO43805: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=121, Recruiting, Hoffmann-La Roche | Trial completion date: Mar 2029 --> Sep 2029 | Trial primary completion date: Mar 2027 --> Sep 2029
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb) • iberdomide (CC-220) • Columvi (glofitamab-gxbm) • golcadomide (CC-99282)
    5ms
    Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 For Diffuse Large B-Cell Lymphoma. (PubMed, Blood Cancer Discov)
    Golcadomide exhibited rapid, deep, and sustained degradation of transcription factors IKZF1 and IKZF3, surpassing the anti-tumor activity of the IMiD® agent lenalidomide in preclinical models. Pharmacological and CRISPR screening further revealed genes and pathways underlying golcadomide's antitumor efficacy. These findings supported golcadomide as a promising drug candidate for DLBCL, providing a strong rationale for future golcadomide-based regimens.
    Journal
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon) • IKZF3 (IKAROS Family Zinc Finger 3)
    |
    lenalidomide • golcadomide (CC-99282)
    8ms
    TOP-FLOR: Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Olivia Newton-John Cancer Research Institute | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive • LDH elevation
    |
    Opdivo (nivolumab) • Rituxan (rituximab) • golcadomide (CC-99282)
    8ms
    FIL_RICCO: A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL) (clinicaltrials.gov)
    P2, N=47, Recruiting, Fondazione Italiana Linfomi - ETS | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • golcadomide (CC-99282)